Harris Perlman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Harris Perlman has a total of 472 co-authors. Here are the top co-authors by number of shared publications:
- Carla Marie Cuda
Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
21 shared publications - Alexander V. Misharin
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
18 shared publications - G. R. Scott Budinger
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, USA
11 shared publications - Richard M. Pope
Northwestern University Feinberg School of Medicine, Chicago, Illinois
9 shared publications - Hiam Abdala-Valencia
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
7 shared publications - Ankit Bharat
Division of Thoracic Surgery, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
5 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Wiley in Arthritis & Rheumatology
CD248 /Endosialin Regulates Synovial Fibroblast State to Control Coupling of Inflammation and Bone Damage in Murine Models of Immune‐Mediated Inflammatory Arthritis and Aging
Objective: Synovial fibroblasts directly contribute to inflammation and damage in immune‐mediated inflammatory arthritis. CD248/endosialin is expressed by fibroblasts in the synovium, is highly up‐regulated during inflammation, and has been proposed as a potential therapeutic target. This study aimed to map the expression of CD248 in disease‐associated fibroblast states and to elucidate its role in pathology. Methods: Molecular profiling of stromal cells from healthy and arthritic (K/BxN serum transfer‐induced arthritis) wildtype ( Cd248 +/+ ) and Cd248 −/− mice was performed using 3′ single‐cell RNA sequencing. Arthritis trajectory and severity were assessed in both genotypes by clinical scoring, microcomputed tomography (micro‐CT), histology, and flow cytometry of dissociated synovium. Additionally, healthy mice of each genotype were aged to 20 months and hind limbs assessed by micro‐CT and histology. Results: Cells expressing high levels of Cd248 also express the “ Pi16 ” fibroblast progenitor gene signature. Genetic deletion of Cd248 in mice altered the differentiation trajectory of these progenitors, predisposing them to become destructive lining layer fibroblasts. Consequently, Cd248 −/− arthritic mice showed a phenotype of rapid, extensive bone damage. Unexpectedly, bone erosion and resultant deformity were also observed in aged Cd248 −/− mice in the absence of an inflammatory stimulus. Conclusion: Genetic deletion of Cd248 −/− results in uncoupling of inflammation and damage due to dysregulated fibroblast progenitor differentiation. Our data suggest that the high levels of CD248 expression seen on synovial fibroblasts provides a protective brake that attenuates bone damage by preventing the polarization of emergent fibroblasts toward a destructive phenotype. Therapeutic targeting of this protein may exacerbate disease.
- 30 September 2026
- Published by Wiley in Arthritis & Rheumatology
Open AccessCD248 /Endosialin Regulates Synovial Fibroblast State to Control Coupling of Inflammation and Bone Damage in Murine Models of Immune‐Mediated Inflammatory Arthritis and Aging
Objective: Synovial fibroblasts directly contribute to inflammation and damage in immune‐mediated inflammatory arthritis. CD248/endosialin is expressed by fibroblasts in the synovium, is highly up‐regulated during inflammation, and has been proposed as a potential therapeutic target. This study aimed to map the expression of CD248 in disease‐associated fibroblast states and to elucidate its role in pathology. Methods: Molecular profiling of stromal cells from healthy and arthritic (K/BxN serum transfer‐induced arthritis) wildtype ( Cd248 +/+ ) and Cd248 −/− mice was performed using 3′ single‐cell RNA sequencing. Arthritis trajectory and severity were assessed in both genotypes by clinical scoring, microcomputed tomography (micro‐CT), histology, and flow cytometry of dissociated synovium. Additionally, healthy mice of each genotype were aged to 20 months and hind limbs assessed by micro‐CT and histology. Results: Cells expressing high levels of Cd248 also express the “ Pi16 ” fibroblast progenitor gene signature. Genetic deletion of Cd248 in mice altered the differentiation trajectory of these progenitors, predisposing them to become destructive lining layer fibroblasts. Consequently, Cd248 −/− arthritic mice showed a phenotype of rapid, extensive bone damage. Unexpectedly, bone erosion and resultant deformity were also observed in aged Cd248 −/− mice in the absence of an inflammatory stimulus. Conclusion: Genetic deletion of Cd248 −/− results in uncoupling of inflammation and damage due to dysregulated fibroblast progenitor differentiation. Our data suggest that the high levels of CD248 expression seen on synovial fibroblasts provides a protective brake that attenuates bone damage by preventing the polarization of emergent fibroblasts toward a destructive phenotype. Therapeutic targeting of this protein may exacerbate disease.
- Open Access
Identity, ontogeny, and age-related changes in splenic white pulp macrophages in mouse and human spleen
The spleen contains diverse macrophage subsets that remove aged erythrocytes, prevent the dissemination of circulating pathogens, and shape the adaptive immune response 1–3 . The mouse spleen hosts red pulp macrophages (RPM), marginal zone macrophages (MZM), marginal zone metallophilic macrophages (MMM), and tingible body macrophages (TBM). However, their transcriptomic identity, ontogeny, and dynamics during aging are unknown. Furthermore, it is not known whether homologous populations of macrophages exist in the human spleen. We find that in mice, MZM and MMM are tissue-resident macrophages that maintain their population via local proliferation, while TBM are slowly replaced by circulating monocytes. Lineage tracing shows that MMM maintain the MZM pool, and that after MMM depletion, circulating monocytes restore MMM. We show that a decrease in MMM abundance in aging precedes changes in other cellular populations and splenic niches. In human spleen, we identify TBM and perifollicular zone macrophages (PFZM) as a single macrophage population homologous to MMM and MZM in mice. We show that in both mouse and human TBM become more abundant during aging. Our results suggest age-related changes in the splenic microenvironment drive changes in tissue-resident splenic macrophage populations with potential importance for the loss of immunologic function in older individuals.
Open AccessIdentity, ontogeny, and age-related changes in splenic white pulp macrophages in mouse and human spleen
The spleen contains diverse macrophage subsets that remove aged erythrocytes, prevent the dissemination of circulating pathogens, and shape the adaptive immune response 1–3 . The mouse spleen hosts red pulp macrophages (RPM), marginal zone macrophages (MZM), marginal zone metallophilic macrophages (MMM), and tingible body macrophages (TBM). However, their transcriptomic identity, ontogeny, and dynamics during aging are unknown. Furthermore, it is not known whether homologous populations of macrophages exist in the human spleen. We find that in mice, MZM and MMM are tissue-resident macrophages that maintain their population via local proliferation, while TBM are slowly replaced by circulating monocytes. Lineage tracing shows that MMM maintain the MZM pool, and that after MMM depletion, circulating monocytes restore MMM. We show that a decrease in MMM abundance in aging precedes changes in other cellular populations and splenic niches. In human spleen, we identify TBM and perifollicular zone macrophages (PFZM) as a single macrophage population homologous to MMM and MZM in mice. We show that in both mouse and human TBM become more abundant during aging. Our results suggest age-related changes in the splenic microenvironment drive changes in tissue-resident splenic macrophage populations with potential importance for the loss of immunologic function in older individuals.
- 14 November 2025
- Published by Springer Nature
- p. 14-23
Imaging-Based Mortality Prediction in Patients with Systemic Sclerosis
- 14 November 2025
- Published by Springer Nature
- p. 14-23
Imaging-Based Mortality Prediction in Patients with Systemic Sclerosis
- Open Access
Profibrotic monocyte-derived alveolar macrophages as a biomarker and therapeutic target in systemic sclerosis-associated interstitial lung disease
Interstitial lung disease (ILD) is present in over 60% of patients with systemic sclerosis (SSc) and is the leading cause of SSc-related deaths. Profibrotic monocyte-derived alveolar macrophages (MoAM) play a causal role in the pathogenesis of pulmonary fibrosis in animal models where their persistence in the niche requires signaling through Colony Stimulating Factor 1 Receptor (CSF1R). We hypothesized that the presence and proportion of MoAM in bronchoalveolar lavage (BAL) fluid from patients with SSc-ILD may be a biomarker of ILD severity. To test this hypothesis, we analyzed BAL fluid from 9 prospectively enrolled patients with SSc-ILD and 13 healthy controls using flow cytometry and single-cell RNA sequencing. Patients with SSc-ILD had more MoAM and interstitial macrophages in BAL fluid than healthy controls, and their abundance was associated with lung fibrosis severity. We identified changes in the MoAM transcriptome as a function of treatment with mycophenolate, an effective therapy for SSc-ILD. In SSc-ILD lung explants, spatial transcriptomics identified an expanded population of interstitial macrophages spilling into the alveolar space. Our findings suggest that the proportion of profibrotic MoAM and interstitial macrophages in BAL fluid may serve as a biomarker of SSc-ILD and credential them as possible targets for therapy.
Open AccessProfibrotic monocyte-derived alveolar macrophages as a biomarker and therapeutic target in systemic sclerosis-associated interstitial lung disease
Interstitial lung disease (ILD) is present in over 60% of patients with systemic sclerosis (SSc) and is the leading cause of SSc-related deaths. Profibrotic monocyte-derived alveolar macrophages (MoAM) play a causal role in the pathogenesis of pulmonary fibrosis in animal models where their persistence in the niche requires signaling through Colony Stimulating Factor 1 Receptor (CSF1R). We hypothesized that the presence and proportion of MoAM in bronchoalveolar lavage (BAL) fluid from patients with SSc-ILD may be a biomarker of ILD severity. To test this hypothesis, we analyzed BAL fluid from 9 prospectively enrolled patients with SSc-ILD and 13 healthy controls using flow cytometry and single-cell RNA sequencing. Patients with SSc-ILD had more MoAM and interstitial macrophages in BAL fluid than healthy controls, and their abundance was associated with lung fibrosis severity. We identified changes in the MoAM transcriptome as a function of treatment with mycophenolate, an effective therapy for SSc-ILD. In SSc-ILD lung explants, spatial transcriptomics identified an expanded population of interstitial macrophages spilling into the alveolar space. Our findings suggest that the proportion of profibrotic MoAM and interstitial macrophages in BAL fluid may serve as a biomarker of SSc-ILD and credential them as possible targets for therapy.
- Open Access
Machine Learning Analysis of Electronic Health Records Identifies Interstitial Lung Disease and Predicts Mortality in Patients with Systemic Sclerosis
Background: Interstitial lung disease (ILD) affects > 40% of patients with systemic sclerosis (SSc/scleroderma) and is the leading cause of disease-related mortality. Although therapies may slow progression, outcomes remain poor, partly because ILD is often detected after irreversible lung injury has occurred. Although chest computed tomography (CT) is a sensitive tool for ILD detection and is recommended at SSc diagnosis, it is oftentimes not performed and even less often performed serially. We sought to develop tools to predict ILD and mortality in patients with SSc using data routinely available in the electronic health record (EHR) to inform medical decision-making. Methods: We analyzed longitudinal EHR data from two SSc cohorts: Northwestern University (1,169 participants; derivation cohort) and Yale University (376 participants; validation cohort). We identified clinical features from existing cohort-linked EHR queries composing a convenience sample of data from participants spanning decades rather than employing a single unified data collection effort. Three ILD experts independently reviewed CT reports and classified each as having or lacking ILD. To explore derivation cohort data structure, patients with > =3 forced vital capacity (FVC) results available were identified and stratified according to prevalent or absent ILD. Using unsupervised trajectory-based clustering exploratory analyses, we determined standardized patterns across groups. ML models were then developed using clinical EHR data as predictor variables and prevalent ILD and all-cause mortality as outcome variables. Model performance was assessed using area under the receiver operating characteristic curve (AUC). Results: Seventy-four clinical features with low missingness, including demographic, vital sign, laboratory, and pulmonary function test data, were utilized for analyses. Four robust PFT trajectory clusters were identified that were associated with ILD prevalence and mortality in exploratory analyses. A ML model for ILD detection achieved an AUC of 0.832 and retained performance in the Yale cohort (AUC 0.754). In addition to established predictors such as autoantibodies and pulmonary function, the model identified routine laboratory measurements, including red cell distribution width (RDW), white blood cell count, and serum chloride, as important contributors. One-year mortality prediction achieved AUCs of 0.904 in the North-western cohort and 0.910 in the Yale cohort. Among patients with SSc-ILD, one-year mortality was predicted with AUCs of 0.744 and 0.902 in the Northwestern and Yale cohorts, respectively. Unexpectedly, we found that subtle laboratory abnormalities (such as change in RDW) contributed to predicting mortality. Conclusions: Our prediction models comprised of widely available EHR data are useful tools to identify SSc patients at high risk for prevalent ILD and all-cause mortality. Integration of these models into clinical practice could enable scalable risk stratification and inform individualized ILD screening and monitoring strategies for SSc patients.
Open AccessMachine Learning Analysis of Electronic Health Records Identifies Interstitial Lung Disease and Predicts Mortality in Patients with Systemic Sclerosis
Background: Interstitial lung disease (ILD) affects > 40% of patients with systemic sclerosis (SSc/scleroderma) and is the leading cause of disease-related mortality. Although therapies may slow progression, outcomes remain poor, partly because ILD is often detected after irreversible lung injury has occurred. Although chest computed tomography (CT) is a sensitive tool for ILD detection and is recommended at SSc diagnosis, it is oftentimes not performed and even less often performed serially. We sought to develop tools to predict ILD and mortality in patients with SSc using data routinely available in the electronic health record (EHR) to inform medical decision-making. Methods: We analyzed longitudinal EHR data from two SSc cohorts: Northwestern University (1,169 participants; derivation cohort) and Yale University (376 participants; validation cohort). We identified clinical features from existing cohort-linked EHR queries composing a convenience sample of data from participants spanning decades rather than employing a single unified data collection effort. Three ILD experts independently reviewed CT reports and classified each as having or lacking ILD. To explore derivation cohort data structure, patients with > =3 forced vital capacity (FVC) results available were identified and stratified according to prevalent or absent ILD. Using unsupervised trajectory-based clustering exploratory analyses, we determined standardized patterns across groups. ML models were then developed using clinical EHR data as predictor variables and prevalent ILD and all-cause mortality as outcome variables. Model performance was assessed using area under the receiver operating characteristic curve (AUC). Results: Seventy-four clinical features with low missingness, including demographic, vital sign, laboratory, and pulmonary function test data, were utilized for analyses. Four robust PFT trajectory clusters were identified that were associated with ILD prevalence and mortality in exploratory analyses. A ML model for ILD detection achieved an AUC of 0.832 and retained performance in the Yale cohort (AUC 0.754). In addition to established predictors such as autoantibodies and pulmonary function, the model identified routine laboratory measurements, including red cell distribution width (RDW), white blood cell count, and serum chloride, as important contributors. One-year mortality prediction achieved AUCs of 0.904 in the North-western cohort and 0.910 in the Yale cohort. Among patients with SSc-ILD, one-year mortality was predicted with AUCs of 0.744 and 0.902 in the Northwestern and Yale cohorts, respectively. Unexpectedly, we found that subtle laboratory abnormalities (such as change in RDW) contributed to predicting mortality. Conclusions: Our prediction models comprised of widely available EHR data are useful tools to identify SSc patients at high risk for prevalent ILD and all-cause mortality. Integration of these models into clinical practice could enable scalable risk stratification and inform individualized ILD screening and monitoring strategies for SSc patients.
- Open Access
- 2 April 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 1
25 years of research and therapy in arthritis
- 2 April 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 1
Open Access25 years of research and therapy in arthritis
- Top Cited PapersOpen Access
- 17 March 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (6)
Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune disease currently with no universally highly effective prevention strategies. Identifying pathogenic immune phenotypes in at-risk populations prior to clinical onset is crucial to establishing effective prevention strategies. Here, we applied multimodal single-cell technologies (mass cytometry and CITE-Seq) to characterize the immunophenotypes in blood from at-risk individuals (ARIs) identified through the presence of serum antibodies against citrullinated protein antigens (ACPAs) and/or first-degree relative (FDR) status, as compared with patients with established RA and people in a healthy control group. We identified significant cell expansions in ARIs compared with controls, including CCR2 + CD4 + T cells, T peripheral helper (Tph) cells, type 1 T helper cells, and CXCR5 + CD8 + T cells. We also found that CD15 + classical monocytes were specifically expanded in ACPA-negative FDRs, and an activated PAX5 lo naive B cell population was expanded in ACPA-positive FDRs. Further, we uncovered the molecular phenotype of the CCR2 + CD4 + T cells, expressing high levels of Th17- and Th22-related signature transcripts including CCR6 , IL23R , KLRB1 , CD96 , and IL22 . Our integrated study provides a promising approach to identify targets to improve prevention strategy development for RA.
- 17 March 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (6)
Top Cited PapersOpen AccessDeep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune disease currently with no universally highly effective prevention strategies. Identifying pathogenic immune phenotypes in at-risk populations prior to clinical onset is crucial to establishing effective prevention strategies. Here, we applied multimodal single-cell technologies (mass cytometry and CITE-Seq) to characterize the immunophenotypes in blood from at-risk individuals (ARIs) identified through the presence of serum antibodies against citrullinated protein antigens (ACPAs) and/or first-degree relative (FDR) status, as compared with patients with established RA and people in a healthy control group. We identified significant cell expansions in ARIs compared with controls, including CCR2 + CD4 + T cells, T peripheral helper (Tph) cells, type 1 T helper cells, and CXCR5 + CD8 + T cells. We also found that CD15 + classical monocytes were specifically expanded in ACPA-negative FDRs, and an activated PAX5 lo naive B cell population was expanded in ACPA-positive FDRs. Further, we uncovered the molecular phenotype of the CCR2 + CD4 + T cells, expressing high levels of Th17- and Th22-related signature transcripts including CCR6 , IL23R , KLRB1 , CD96 , and IL22 . Our integrated study provides a promising approach to identify targets to improve prevention strategy development for RA.
- Open Access
Comprehensive analysis of myeloid reporter mice
Macrophages are a pivotal cell type within the synovial lining and sub-lining of the joint, playing a crucial role in maintaining homeostasis of synovium. Although fate-mapping techniques have been employed to differentiate synovial macrophages from other synovial myeloid cells, no comprehensive study has yet been conducted within the mouse synovial macrophage compartment. In this study, we present, for the first time, lineage tracing results from 18 myeloid-specific fate-mapping models in mouse peripheral blood (PB) and synovial tissue. The identification of synovial macrophages and monocyte-lineage cells through flow cytometry was further validated using cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) datasets. These findings provide a valuable methodological tool for researchers to select appropriate models for studying the function of synovial myeloid cells and serve as a reference for investigations in other tissue types.
Open AccessComprehensive analysis of myeloid reporter mice
Macrophages are a pivotal cell type within the synovial lining and sub-lining of the joint, playing a crucial role in maintaining homeostasis of synovium. Although fate-mapping techniques have been employed to differentiate synovial macrophages from other synovial myeloid cells, no comprehensive study has yet been conducted within the mouse synovial macrophage compartment. In this study, we present, for the first time, lineage tracing results from 18 myeloid-specific fate-mapping models in mouse peripheral blood (PB) and synovial tissue. The identification of synovial macrophages and monocyte-lineage cells through flow cytometry was further validated using cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) datasets. These findings provide a valuable methodological tool for researchers to select appropriate models for studying the function of synovial myeloid cells and serve as a reference for investigations in other tissue types.
- Open Access
- 1 October 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (22)
Inducible CCR2+ nonclassical monocytes mediate the regression of cancer metastasis
A major limitation of immunotherapy is the development of resistance resulting from cancer-mediated inhibition of host lymphocytes. Cancer cells release CCL2 to recruit classical monocytes expressing its receptor CCR2 for the promotion of metastasis and resistance to immunosurveillance. In the circulation, some CCR2-expressing classical monocytes lose CCR2 and differentiate into intravascular nonclassical monocytes that have anticancer properties but are unable to access extravascular tumor sites. We found that in mice and humans, an ontogenetically distinct subset of naturally underrepresented CCR2-expressing nonclassical monocytes was expanded during inflammatory states such as organ transplant and COVID-19 infection. These cells could be induced during health by treatment of classical monocytes with small-molecule activators of NOD2. The presence of CCR2 enabled these inducible nonclassical monocytes to infiltrate both intra- and extravascular metastatic sites of melanoma, lung, breast, and colon cancer in murine models, and they reversed the increased susceptibility of Nod2 –/– mutant mice to cancer metastasis. Within the tumor colonies, CCR2 + nonclassical monocytes secreted CCL6 to recruit NK cells that mediated tumor regression, independent of T and B lymphocytes. Hence, pharmacological induction of CCR2 + nonclassical monocytes might be useful for immunotherapy-resistant cancers.
- 1 October 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (22)
Open AccessInducible CCR2+ nonclassical monocytes mediate the regression of cancer metastasis
A major limitation of immunotherapy is the development of resistance resulting from cancer-mediated inhibition of host lymphocytes. Cancer cells release CCL2 to recruit classical monocytes expressing its receptor CCR2 for the promotion of metastasis and resistance to immunosurveillance. In the circulation, some CCR2-expressing classical monocytes lose CCR2 and differentiate into intravascular nonclassical monocytes that have anticancer properties but are unable to access extravascular tumor sites. We found that in mice and humans, an ontogenetically distinct subset of naturally underrepresented CCR2-expressing nonclassical monocytes was expanded during inflammatory states such as organ transplant and COVID-19 infection. These cells could be induced during health by treatment of classical monocytes with small-molecule activators of NOD2. The presence of CCR2 enabled these inducible nonclassical monocytes to infiltrate both intra- and extravascular metastatic sites of melanoma, lung, breast, and colon cancer in murine models, and they reversed the increased susceptibility of Nod2 –/– mutant mice to cancer metastasis. Within the tumor colonies, CCR2 + nonclassical monocytes secreted CCL6 to recruit NK cells that mediated tumor regression, independent of T and B lymphocytes. Hence, pharmacological induction of CCR2 + nonclassical monocytes might be useful for immunotherapy-resistant cancers.
- Open Access
- 16 November 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (4) , 577-590
Temporal correlation between postreperfusion complement deposition and severe primary graft dysfunction in lung allografts
- 16 November 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (4) , 577-590
Open AccessTemporal correlation between postreperfusion complement deposition and severe primary graft dysfunction in lung allografts